Venetoclax Plus Lenalidomide
Phase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) in t(11;14) Multiple Myeloma
Arms / Cohorts
Experimental, Arm B:Venetoclax + Lenalidomide + Dexamethasone
Accepting patients
Experimental, Arm A:Venetoclax + Daratumumab + Dexamethasone
Accepting patients
Experimental, Arm C:Venetoclax + Daratumumab + Lenalidomide + Dexamethasone
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.